Therapeutic Advances in Psychopharmacology (TAP)

Therapeutic Advances in Psychopharmacology is an international, peer-reviewed, fully open-access medical journal that publishes high-quality research on the clinical use of medications for psychiatric and neurological disorders. Established in 2011 by SAGE Publishing in collaboration with the British Association for Psychopharmacology, the journal provides a platform for clinicians, psychiatrists, neuroscientists, pharmacologists, psychologists, and mental health researchers to share innovative findings in psychopharmacology. The journal publishes original research articles, systematic reviews, meta-analyses, clinical trials, case reports, brief reports, and expert commentaries covering the discovery, development, evaluation, and clinical application of psychotropic medications. Major topics include antidepressants, antipsychotics, anxiolytics, mood stabilizers, cognitive enhancers, psychedelic therapies, substance use disorders, treatment-resistant psychiatric conditions, pharmacogenomics, neuropsychopharmacology, medication safety, and personalized medicine. It also features research on drug efficacy, adverse effects, pharmacokinetics, pharmacodynamics, and evidence-based prescribing practices. All submissions undergo rigorous peer review to ensure scientific quality and clinical relevance. The journal is indexed in major international databases, including PubMed, PubMed Central, Web of Science (SCIE), and Scopus, providing wide visibility and accessibility. Its Gold Open Access model enables immediate worldwide access to published research, facilitating the rapid dissemination of advances in psychiatric pharmacotherapy.

Therapeutic Advances in Psychopharmacology (TAP) is :-

• International, Peer-Reviewed, Open Access, Refereed, Psychopharmacology, Psychiatry, Clinical Pharmacology, Neuropsychopharmacology, Mental Health, Drug Therapy, Pharmacogenomics, Clinical Neuroscience, Therapeutics, Evidence-Based Medicine, antidepressants, antipsychotics, anxiolytics, mood stabilizers, cognitive enhancers, psychedelic therapies, substance use disorders, treatment-resistant psychiatric conditions, pharmacogenomics, neuropsychopharmacology, medication safety, personalized medicine , Online or Print , Bi-Monthly Journal

• UGC Approved, ISSN Approved: P-ISSN P-ISSN: 2045-1253, E-ISSN: 2045-1261, Established: 2011,
• Does Not Provide Crossref DOI

• Not indexed in Scopus, WoS, DOAJ, PubMed, UGC CARE